Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform

BACKGROUND: Interleukin 6 concentration is associated with myocardial injury, heart failure, and mortality after myocardial infarction. In the Norwegian tocilizumab non–ST‐segment–elevation myocardial infarction trial, the first randomized trial of interleukin 6 blockade in myocardial infarction, co...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Marc J., Kleveland, Ola, Garcia‐Hernandez, Jorge, Palmen, Jutta, Lovering, Ruth, Wiseth, Rune, Aukrust, Pål, Engmann, Jorgen, Damås, Jan Kristian, Hingorani, Aroon D., Gullestad, Lars, Casas, Juan P., Ueland, Thor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429051/
https://www.ncbi.nlm.nih.gov/pubmed/32515246
http://dx.doi.org/10.1161/JAHA.119.015628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429051/
https://www.ncbi.nlm.nih.gov/pubmed/32515246
http://dx.doi.org/10.1161/JAHA.119.015628

Ejemplares similares